Emory's Jonathan Cohen, MD, Traces Evolution in CLL Therapy
Coverage from the July 25, 2023, session of the Institute for Value-Based Medicine®, held in partnership with Emory's Winship Cancer Institute.
Source: ajmc.com
Page 5 - Lymphoma Program News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Stay updated with breaking news from Lymphoma Program. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Top News In Lymphoma Program Today - Breaking & Trending Today
BrECADD Proves Noninferior to eBEACOPP in Advanced Classical Hodgkin Lymphoma
The BrECADD combination had noninferior efficacy and superior tolerability compared with escalated BEACOPP in patients with advanced classical Hodgkin lymphoma, according to data from the phase 3 HD21 trial.
Source: onclive.com
Phase 3 Trial of ADCETRIS® (brentuximab vedotin) with Modified Chemo Regimen Shows Non-Inferiority with Unprecedented 3-Year Progression Free Survival of 94.9% vs Less Tolerable International Standard of Care in Advanced Classical Hodgkin Lymphoma
– Results are from 1,500 patient trial conducted by German Hodgkin Study Group to test ADCETRIS regimen versus international standard eBEACOPP therapy – ADCETRIS regimen showed less... | June 20, 2023
Source: marketscreener.com
FDA Approves Roche Lymphoma Drug, Bringing Competition to New AbbVie Med
The FDA approved Roche’s Columvi as a third-line treatment for a type of blood cancer called diffuse large B-cell lymphoma. This new Roche drug will compete against Epkinly, AbbVie’s recently approved DLBCL drug.
Source: medcitynews.com
FDA Approves Genentech's Columvi, the First and Only Bispecific Antibody With a Fixed-Duration Treatment for People With Relapsed or Refractory Diffuse Large B-cell Lymphoma | Business
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Jun 15, 2023--
Source: valdostadailytimes.com